Research Article
No access
Published Online: 15 December 2005

Graves' Disease: A Long-Term Quality-of-Life Follow Up of Patients Randomized to Treatment with Antithyroid Drugs, Radioiodine, or Surgery

Publication: Thyroid
Volume 15, Issue Number 11


The effects of treatment modality for Graves' disease (GD) were studied with respect to long-term quality of life and present health status. A total of 179 patients with GD were randomized during the period 1983–1990 for treatment with antithyroid drugs, radioiodine, or surgery. A 36-item Short Form Health Status Survey questionnaire and specific questions for GD were sent to patients 14–21 years after randomization. Present medical records, and clinical and laboratory status were recorded. No major significant differences in quality of life among the three treatments were observed. Compared to a large Swedish reference group, all treatment groups had significantly lower scores for vitality (p < 0.05). The Mental Component Summary was lower for both the young medical, young surgical, and the older medical group (p < 0.05). Radioiodine-treated patients had a lower General Health score. Young medical patients (<35 years) had lower Mental Health scores (p < 0.05). There was also a strong trend, which barely met statistically significance, for older surgical and radioiodine groups for lower Mental Component Summary. GD patients have, compared with a large Swedish reference population, diminished vital and mental quality of life aspects even many years after treatment. The qualityof- life scores were not different among the three treatment modalities.

Get full access to this article

View all available purchase options and get full access to this article.

Information & Authors


Published In

cover image Thyroid®
Volume 15Issue Number 11November 2005
Pages: 1279 - 1286
PubMed: 16356093


Published online: 15 December 2005
Published in print: November 2005


Request permissions for this article.




Mirna Abraham-Nordling
Department of Surgery, Karolinska University Hospital, Solna, Sweden.
Ove Törring
Endocrine Section, Department of Medicine, Sodersjukhuset, Stockholm, Sweden.
Bertil Hamberger
Department of Surgery, Karolinska University Hospital, Solna, Sweden.
Göran Lundell
Department of Oncology, Karolinska University Hospital, Solna, Sweden.
Leif Tallstedt
St. Erik Eye Hospital, Stockholm, Sweden.
Jan Calissendorff
Department of Endocrinology, Karolinska University Hospital, Solna, Sweden.
Göran Wallin
Department of Surgery, Karolinska University Hospital, Solna, Sweden.

Metrics & Citations



Export citation

Select the format you want to export the citations of this publication.

View Options

Get Access

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options


View PDF/ePub







Copy the content Link

Share on social media

Back to Top